Adaptimmune Therapeutics PLC: Results of Adaptimmune s SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.
The data confirm the pre|CISIONTM platform s ability to transform the safety profile of doxorubicin through tumour targeting Cohort 7, the final cohort in the three-weekly dose.
The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.
Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.